QNCX Quince Therapeutics
- 1.060
- +0.030+2.91%
- 1.000
- -0.060-5.66%
Quince Therapeutics News
Quince Therapeutics | ARS: Annual Report to Security Holders
Quince Therapeutics | DEFA14A: Others
Quince Therapeutics | DEF 14A: Definitive information statements
Quince Therapeutics | PRE 14A: Preliminary proxy statements relating to merger or acquisition
Quince Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Quince Therapeutics | 10-K: Annual report
Quince Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Patni Rajiv
Quince Therapeutics | 3: Initial statement of beneficial ownership of securities-Director Patni Rajiv
Quince Therapeutics | 8-K: Current report
Quince Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-TANG CAPITAL PARTNERS, LP(7.5%),Tang Capital Management, LLC(7.5%), etc.
Quince Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-Sofinnova Capital VIII (“SC VIII”)(5.1%),Sofinnova Partners SAS, a French corporation (“SP SAS”)(5.1%), etc.
Quince Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-BML Investment Partners, L.P.(0.0%),Braden M Leonard(0.0%)
Quince Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Ryan Charles S.
Quince Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Hannah Brendan
Quince Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Thye Dirk
Quince Therapeutics | 8-K: Current report
Quince Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Thye Dirk
Quince Therapeutics | 8-K/A: Current report (Amendment)
Quince Therapeutics | 8-K: Current report
Quince Therapeutics | 8-K: Current report
Analysis
Price Target
No Data
